These emerging therapies , Semaglutide , represent a groundbreaking advancement in addressing type 2 diabetes and possibly related ailments . They are categorized as GLP-1 pathway agonists , indicating https://deborahobaw616226.blogscribble.com/41638441/tirzepatide-a-thorough-dive-into-incretin-agents